| Chemosensitivity Testing in Oncology 2003 Edition Contributor(s): Reinhold, Uwe (Editor), Tilgen, Wolfgang (Editor) |
|
 |
ISBN: 3540434682 ISBN-13: 9783540434689 Publisher: Springer OUR PRICE: $161.49 Product Type: Hardcover - Other Formats Published: October 2002 Annotation: The last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of new in vitro chemosensitivity assays. The clinical utility of drug response assays has been evaluated in clinical trials and the results suggest that assay-assisted therapy selection may improve survival as well as economic outcomes. This volume comprises the proceedings of the first Symposium of the International Society for Chemosensitivity Testing in Oncology, ISCO-1, held in Homburg/Saar, Germany, in September 2001. The topics include: new in vitro drug-testing methods, tumor chemosensitivity assays, and the clinical relevance of assay-directed therapy. |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Forensic Medicine - Science | Life Sciences - General |
| Dewey: 614.599 |
| LCCN: 2002066990 |
| Series: Recent Results in Cancer Research |
| Physical Information: 0.58" H x 6.14" W x 9.42" (1.05 lbs) 245 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells. |
